Published in Infect Immun on June 27, 2011
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
Structural vaccinology starts to deliver. Nat Rev Microbiol (2012) 1.22
Meningococcal disease and the complement system. Virulence (2013) 1.19
The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog (2012) 1.17
Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc Natl Acad Sci U S A (2013) 1.16
Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. MBio (2014) 1.13
Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun (2011) 1.06
Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun (2011) 1.06
Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine (2013) 1.05
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev (2013) 1.05
The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol (2012) 1.04
Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis (2013) 1.01
Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine. J Infect Dis (2015) 1.00
Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun (2012) 0.99
A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp. Sci Rep (2012) 0.97
Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine. Clin Vaccine Immunol (2015) 0.92
Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines. Clin Vaccine Immunol (2014) 0.91
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease. Hum Vaccin Immunother (2014) 0.91
Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PLoS One (2012) 0.89
Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa. PLoS One (2013) 0.86
Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity. Infect Immun (2015) 0.86
A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens. PLoS One (2015) 0.84
fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. Vaccine (2013) 0.82
Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein. MBio (2015) 0.80
Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine. Vaccine (2015) 0.80
A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice. Vaccine (2015) 0.79
A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine. Vaccine (2015) 0.79
Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice. Infect Immun (2015) 0.78
Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice. Clin Vaccine Immunol (2011) 0.78
Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity. Clin Vaccine Immunol (2016) 0.78
Protein Crystallography in Vaccine Research and Development. Int J Mol Sci (2015) 0.77
The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine (2017) 0.75
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 6.26
Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 5.63
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Complement evasion by human pathogens. Nat Rev Microbiol (2008) 4.24
The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol (2004) 4.16
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun (2004) 3.29
Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol (1981) 3.04
Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine (2005) 2.81
Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature (2009) 2.81
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun (2008) 2.29
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol (2004) 2.13
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis (2008) 2.00
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol (1998) 1.75
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
Interactions between Neisseria meningitidis and the complement system. Trends Microbiol (2007) 1.72
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol (2011) 1.68
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine (2010) 1.67
Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun (2008) 1.61
Review of meningococcal group B vaccines. Clin Infect Dis (2010) 1.58
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine (2009) 1.58
Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis (2009) 1.47
Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine (2009) 1.42
Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem (2008) 1.38
Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol (1991) 1.36
Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis (2010) 1.20
Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J Mol Biol (2008) 1.17
Binding of human factor H-related protein 1 to serum-resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J Infect Dis (2007) 1.17
A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol (2009) 1.16
The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun (2002) 1.14
Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun (2010) 1.11
Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine (2011) 1.11
Quadrivalent meningococcal conjugate vaccines. Vaccine (2009) 1.09
Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine (2009) 1.08
Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol (2008) 1.08
Bypassing complement: evolutionary lessons and future implications. J Clin Invest (2006) 1.07
Effects of complement regulators bound to Escherichia coli K1 and Group B Streptococcus on the interaction with host cells. Immunology (2007) 1.05
Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun (2005) 1.05
Microbial complement inhibitors as vaccines. Vaccine (2008) 1.05
Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol (2006) 1.04
Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol (2010) 0.98
Structural stability and heat-induced conformational change of two complement inhibitors: C4b-binding protein and factor H. Protein Sci (2004) 0.91
Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Rev Vaccines (2009) 0.85
Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis. Infect Immun (2000) 0.82
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
Development of vaccines against meningococcal disease. Lancet (2002) 2.67
Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet (2003) 2.21
Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol (2004) 2.13
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis (2008) 2.00
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol (2011) 1.68
Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun (2008) 1.66
Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect Immun (2002) 1.62
Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun (2008) 1.61
Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine (2009) 1.42
Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis (2006) 1.39
Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun (2002) 1.29
Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis (2011) 1.27
Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis (2005) 1.25
Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol (2009) 1.24
Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B. Infect Immun (2004) 1.24
The modular architecture of meningococcal factor H-binding protein. Microbiology (2009) 1.24
Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol (2008) 1.22
Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis (2008) 1.19
Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. Mol Microbiol (2006) 1.17
The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog (2012) 1.17
Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun (2003) 1.12
Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun (2010) 1.11
Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine (2011) 1.11
Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis (2007) 1.08
Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun (2011) 1.06
Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun (2011) 1.06
Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine (2013) 1.05
Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol (2006) 1.04
Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. MBio (2013) 1.02
Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis (2013) 1.01
Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine (2011) 1.00
Molecular ontogeny of the human antibody repertoire to the Haemophilus influenzae type B polysaccharide: expression of canonical variable regions and their variants in vaccinated infants. Clin Immunol (2003) 0.99
Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun (2012) 0.99
Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol (2010) 0.98
A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol (2011) 0.97
A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp. Sci Rep (2012) 0.97
Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun (2003) 0.96
Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine (2006) 0.96
Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis (2003) 0.92
Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect Immun (2005) 0.90
Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Mol Immunol (2005) 0.90
Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PLoS One (2012) 0.89
Paratope diversity in the human antibody response to Bacillus anthracis protective antigen. Mol Immunol (2007) 0.88
Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa. PLoS One (2013) 0.86
Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect Immun (2014) 0.86
Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol (2006) 0.85
Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine (2005) 0.84
Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization. J Infect Dis (2006) 0.82
fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. Vaccine (2013) 0.82
Immune status of infants fed soy-based formulas with or without added nucleotides for 1 year: part 1: vaccine responses, and morbidity. J Pediatr Gastroenterol Nutr (2002) 0.80
Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pediatr Infect Dis J (2004) 0.78
Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population. J Am Geriatr Soc (2004) 0.77
Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan. Hum Vaccin (2007) 0.76
Comment on "Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates". J Immunol (2009) 0.75
Somatic diversity in CDR3 loops allows single V-genes to encode innate immunological memories for multiple pathogens. J Immunol (2011) 0.75